Exploring gaps in GLP-1 research, care, and coverage

Healthcare Strategies

Conteúdo fornecido por Xtelligent Healthcare Media. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Xtelligent Healthcare Media ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

1M ago 16:35

MP3•Home de episódios

GLP-1 drugs, like Ozempic, Wegovy, and Zepbound, have gained attention for their significant health impacts and anti-obesity effects. However, there continues to be a lot of unknowns surrounding these medications, their long-term impacts, and access.

Featuring: Dr. Lydia Alexander, an obesity medicine specialist, lifestyle specialist, president of the Obesity Medicine Association (OMA), Chief Medical Officer at Enara, and a medical chef.

In today’s episode, we’ll cover

The significant progress made in GLP-1 research, care delivery, and insurance coverage
Filling research gaps in GLP-1 care through longitudinal studies examining long-term medication effects and potential adverse reactions
Tips for providers managing patients on GLP-1 medications and patient-focused approaches to obesity management

And more!

To watch video clips from our podcast, subscribe to our YouTube channel, @Healthcare Strategies

Resources:

120 episódios

#Business #Healthcare Strategies #Xtelligent Healthcare Media